Search for 'multiple sclerosis'

Search in texts for 'multiple sclerosis' - Neurosonology.net'

Download page (1)

90 results of 16 texts with exact phrase : 'multiple sclerosis'.

1. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 1, 2005, No. 2 , , ,

Multiple Sclerosis,
Multiple Sclerosis,
read the entire text >>

22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
read the entire text >>

2. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 3, 2007, No. 2 , , ,

MS Academia – Multiple Sclerosis Advanced Course
MS Academia – Multiple Sclerosis Advanced Course
read the entire text >>

3. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 4, 2008, No. 1 , , ,

and Investigation of Multiple Sclerosis (ECTRIMS)
and Investigation of Multiple Sclerosis (ECTRIMS)
read the entire text >>

23th Congress of the European Committee for Treatment and Investigation of Multiple Sclerosis (ECTRIMS)
23th Congress of the European Committee for Treatment and Investigation of Multiple Sclerosis (ECTRIMS)
read the entire text >>

Consortium of Multiple Sclerosis Centers (CMSC)
Consortium of Multiple Sclerosis Centers (CMSC)
read the entire text >>

4. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 4, 2008, No. 1 , , ,

Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.
Zamboni, P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall’Ara S, Bartolomei I, Salvi F. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.
read the entire text >>

Research in Multiple Sclerosis
Research in Multiple Sclerosis
read the entire text >>

5. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 6, 2010, No. 1 , , ,

She has been awarded sixteen research awards including the “Eduardo Liceaga Prize” awarded by the National Academy of Medicine (1986) the Latin American Committee for the Treatment and Research in Multiple Sclerosis (2002), the Merit Award for Public Health Professionals and the “Manuel Velasco Suarez Award” from the Mexican General
She is a senior researcher from the National Institutes of Health and member of the National Researcher’s System (Level II), from the Mexican Council of Science and Technology (CONACYT). She has 225 national and international publications in peer reviewed journals and presentations in academic fora. She has been awarded sixteen research awards including the “Eduardo Liceaga Prize” awarded by the National Academy of Medicine (1986) the Latin American Committee for the Treatment and Research in Multiple Sclerosis (2002), the Merit Award for Public Health Professionals and the “Manuel Velasco Suarez Award” from the Mexican General
read the entire text >>

Dr. Corona is a member of 20 national and international societies, including the Mexican Academy of Sciences, the World Federation of Neurology, the American Academy of Neurology, the Consortium of Multiple Sclerosis Centers, the Spanish Society of Neurology and Honorary Member, Colombian Association of Neurology.
Dr. Corona is a member of 20 national and international societies, including the Mexican Academy of Sciences, the World Federation of Neurology, the American Academy of Neurology, the Consortium of Multiple Sclerosis Centers, the Spanish Society of Neurology and Honorary Member, Colombian Association of Neurology. She was founding President of the National Association of Neurologists of the Mexican Social Security Institute, Treasurer of the Mexican Academy of Neurology and member of the Mexican Council of Neurology. In 2002 Dr. Corona served as Deputy Secretary of the National Academy of Medicine and as Secretary General for the years 2005-2006.
read the entire text >>

World Multiple Sclerosis (MS) Day
World Multiple Sclerosis (MS) Day
read the entire text >>

6. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 7, 2011, No. 2 , , ,

Fingolimod – the First Approved Oral Medication in Multiple Sclerosis
Fingolimod – the First Approved Oral Medication in Multiple Sclerosis
read the entire text >>

Fingolimod – the First Approved Oral Medication in Multiple Sclerosis
Fingolimod – the First Approved Oral Medication in Multiple Sclerosis
read the entire text >>

multiple sclerosis, sphingosine 1-phosphate receptor modulators, TRANSFORMS
multiple sclerosis, sphingosine 1-phosphate receptor modulators, TRANSFORMS
read the entire text >>

(fingolimod), is the first oral drug licensed by the European Medicines Agency as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (MS).
(fingolimod), is the first oral drug licensed by the European Medicines Agency as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (MS). Fingolimod mediates its therapeutic effects through the immune system and directly on the central nervous system (CNS). Fingolimod reduces the recirculation of auto-reactive central memory Tcells and their infiltration in the CNS, where they would cause neurodegeneration. Peripheral lymphocyte count reduction is reversible and reflects the reversible retention of circulating lymphocytes in lymph nodes, but not their depletion. Two large, phase 3 trials – TRANSFORMS and FREEDOMS demonstrated that fingolimod improved the clinical outcome for MS patients – reduced the annualized relapse rate, decreased the risk of confirmed disability progression and reduced the number and volume of brain lesions on MRI images.
read the entire text >>

(fingolimod), is the first oral drug licensed by the European Medicines Agency as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (MS) [1].
(fingolimod), is the first oral drug licensed by the European Medicines Agency as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (MS) [1]. Many other molecules for parenteral and oral administration in MS patients are in different stages of clinical development.
read the entire text >>

Fingolimod – the first approved oral medication in Multiple Sclerosis
Fingolimod – the first approved oral medication in Multiple Sclerosis
read the entire text >>

Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) is a 12-month, multicenter, randomized, double-blind, double-dummy trial in which 1292 patients with relapsingremitting MS with at least one documented relapse during the previous year or at least two documented relapses during the previous 2 years and score from 0 to 5.5 on the Expanded Disability Status Scale (EDSS) were randomized for a 12-month treatment with oral fingolimod, at a daily dose of either 1.25 or 0.5 mg, or intramuscular interferon beta-1a at a weekly dose of 30 mcg [9].
Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) is a 12-month, multicenter, randomized, double-blind, double-dummy trial in which 1292 patients with relapsingremitting MS with at least one documented relapse during the previous year or at least two documented relapses during the previous 2 years and score from 0 to 5.5 on the Expanded Disability Status Scale (EDSS) were randomized for a 12-month treatment with oral fingolimod, at a daily dose of either 1.25 or 0.5 mg, or intramuscular interferon beta-1a at a weekly dose of 30 mcg [9]. The primary efficacy end point was the annualized relapse rate. The two key secondary end points were the number of new or enlarged hyperintense lesions on T2-weighted
read the entire text >>

Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) е 12-месечно, двойно-сляпо, многоцентрово проучване, в което 1292 пациенти с пристъпно-ремитентна форма на МС с анамнеза за поне един документиран пристъп на заболяването в предходната година или два пристъпа през предходните две години и с оценка по скалата на Куртцке (EDSS) от 0 до 5.5, са рандомизирани на лечение с финголимод в дневна доза 1.25 mg или 0.5 mg или с interferon beta-1a, приложен интрамускулно (im), в седмична доза от 30 mcg [9].
Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) е 12-месечно, двойно-сляпо, многоцентрово проучване, в което 1292 пациенти с пристъпно-ремитентна форма на МС с анамнеза за поне един документиран пристъп на заболяването в предходната година или два пристъпа през предходните две години и с оценка по скалата на Куртцке (EDSS) от 0 до 5.5, са рандомизирани на лечение с финголимод в дневна доза 1.25 mg или 0.5 mg или с interferon beta-1a, приложен интрамускулно (im), в седмична доза от 30 mcg [9]. Оценяваният първичeн показател за ефективност е годишната честота на пристъпите. Вторични показатели са: нарастване по големина или поява на нови лезии при провеждане на магнитно-резонансно изобразяване (МРТ) на мозъка след 12 месеца лечение и прогресията на инвалидизацията [9]. Проучването е завършено от 1153 пациенти (89%). Едногодишното проследяване показва, че в сравнение с interferon beta-1a im финголимод намалява значимо годишната честота на пристъпите с 52% [9], намалява до 71% пристъпите, изискващи хоспитализация и понижава с 52% необходимостта от кортикостероиди (р
read the entire text >>

Fingolimod – the first approved oral medication in Multiple Sclerosis
Fingolimod – the first approved oral medication in Multiple Sclerosis
read the entire text >>

Fingolimod – the first approved oral medication in Multiple Sclerosis
Fingolimod – the first approved oral medication in Multiple Sclerosis
read the entire text >>

Fingolimod in Relapsing Multiple Sclerosis.
Fingolimod in Relapsing Multiple Sclerosis.
read the entire text >>

J. Oral Fingolimod (FTY720) Reduces the Rate of Relapses that Require Steroid Intervention or Hospitalization Compared with Intramuscular Interferon β-1a: Results from a Phase III study (TRANSFORMS) in Multiple Sclerosis Abstract P06.170 In: 62nd annual meeting of AAN; April 10-17, 2010, Toronto, Canada.
J. Oral Fingolimod (FTY720) Reduces the Rate of Relapses that Require Steroid Intervention or Hospitalization Compared with Intramuscular Interferon β-1a: Results from a Phase III study (TRANSFORMS) in Multiple Sclerosis Abstract P06.170 In: 62nd annual meeting of AAN; April 10-17, 2010, Toronto, Canada.
read the entire text >>

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RLP, Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
read the entire text >>

7. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 8, 2012, No. 1 , , ,

Multiple Sclerosis (MS).
Multiple Sclerosis (MS).
read the entire text >>

Visual and motor evoked potentials in the course of multiple sclerosis.
Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis.
read the entire text >>

Magnetic brain stimulation: central motor conduction studies in multiple sclerosis.
Hess CW, Mills KR, Murray NMF, Schriefer TN. Magnetic brain stimulation: central motor conduction studies in multiple sclerosis.
read the entire text >>

Demyelination and axonal degeneration in corpus callosum assessed by analysis of transcallosally mediated inhibition in multiple sclerosis.
Hoppner J, Kunesch E, Buchmann J, Hess A, Grossmann A, Benecke R. Demyelination and axonal degeneration in corpus callosum assessed by analysis of transcallosally mediated inhibition in multiple sclerosis.
read the entire text >>

Rehabilitation treatment and interdisciplinary approach may improve the condition of patients with progressive neurologic disorders such as multiple sclerosis, Parkinson’s disease, amyotrophic lateral sclerosis, muscular dystrophy and neuropathy.
Rehabilitation treatment and interdisciplinary approach may improve the condition of patients with progressive neurologic disorders such as multiple sclerosis, Parkinson’s disease, amyotrophic lateral sclerosis, muscular dystrophy and neuropathy. The choice of a wheelchair is crucial in progressive neurologic disorders [1].
read the entire text >>

Neurorehabilitation in multiple sclerosis aims to affect the spasticity, urination problems, sensory and motor impairments, which are treated in a similar way as spinal cord traumas.
Neurorehabilitation in multiple sclerosis aims to affect the spasticity, urination problems, sensory and motor impairments, which are treated in a similar way as spinal cord traumas. Over 40% of the patients have cognitive deficit [26].
read the entire text >>

Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial.
Khan F, Pallant JF, Brand C, Kilpatrick TJ. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial.
read the entire text >>

8. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 9, 2013, No. 1 , , ,

Ultrasound and the Study of the so-called Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis
Ultrasound and the Study of the so-called Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis
read the entire text >>

Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charit
Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charit
read the entire text >>

Multiple sclerosis, Neurosonology, Ultrasound
Multiple sclerosis, Neurosonology, Ultrasound
read the entire text >>

In 2006, Zamboni re-introduced the concept that chronic impaired venous outflow of the CNS is associated with multiple sclerosis (MS), coining the term of chronic cerebrospinal venous insufficiency (“CCSVI”).
In 2006, Zamboni re-introduced the concept that chronic impaired venous outflow of the CNS is associated with multiple sclerosis (MS), coining the term of chronic cerebrospinal venous insufficiency (“CCSVI”). The diagnosis of “CCSVI” is based on sonographic criteria, which he found exclusively fulfilled in MS. The concept proposes that chronic venous outflow failure is associated with venous reflux and congestion and leads to iron deposition, thereby inducing neuroinflammation and degeneration. The revival of this concept has generated major interest in media and patient groups, mainly driven by the hope that endovascular treatment of “CCSVI” could alleviate MS. Many investigators tried to replicate Zamboni’s results with duplex sonography, MRI, and catheter angiography. The data obtained here do generally not support the “CCSVI” concept.
read the entire text >>

In 2006, the vascular surgeon Paolo Zamboni re-introduced the pathophysiological concept of venous outflow pathology ultimately leading to multiple sclerosis (MS) [71].
In 2006, the vascular surgeon Paolo Zamboni re-introduced the pathophysiological concept of venous outflow pathology ultimately leading to multiple sclerosis (MS) [71]. He based this concept (or “the big idea”) on the well-known histopathologic features of a perivenous localization of inflammatory MS lesions. He coined the term “CCSVI” (chronic cerebrospinal venous insufficiency) in analogy to perivenous inflammation in chronic venous insufficiency of the legs. While Zamboni’s approach does not challenge the commonly accepted understanding of MS immunopathology [37], it does relegate it to the final stage in the disease cascade. According to the “CCSVI” concept, MS pathology starts with intracranial venous stasis based on a proximal obstruction of the main cervical and/or thoracic veins. This leads to perivenous diapedesis of erythrocytes in the white matter with subsequent release of iron, the actual catalyst of the widely known and accepted immune cascade [37].
read the entire text >>

Subsequently, they reported improvement in the Multiple Sclerosis Functional Composite (MSFC) in relapsing remitting MS and a reduction of Gadolinium enhancing lesions on brain MRI during a mean follow-up of 18 months in a small monocentric open angioplastic intervention study [66].
ported a correlation of the clinical course of MS with specific patterns of venous obstructions [9]. Subsequently, they reported improvement in the Multiple Sclerosis Functional Composite (MSFC) in relapsing remitting MS and a reduction of Gadolinium enhancing lesions on brain MRI during a mean follow-up of 18 months in a small monocentric open angioplastic intervention study [66]. “CCSVI” and its presumed efficacious therapeutic approach termed “liberation treatment” caused enormous interest in the scientific community, amongst patient support groups and in the media. Several clinical trials on angioplasty have started since, and numerous desperate MS patients seek relief from their incurable disease through questionable medical procedures. However, in the meantime the number of publications that refute the “CCSVI” hypothesis has far exceeded that of its supporters. This review aims to analyse and critically comment on methodical aspects of “CCSVI” in the context of (patho-)physiological plausibility, which refers mainly to color-coded duplex ultrasonography (US), which is the only method according to Zamboni to define “CCSVI”.
read the entire text >>

Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. I
Al-Omari MH, Rousan LA. Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. I
read the entire text >>

Extra-cranial venous flow in patients with multiple sclerosis.
Auriel E, Karni A, Bornstein NM, Nissel T, Gadoth A, Hallevi H. Extra-cranial venous flow in patients with multiple sclerosis.
read the entire text >>

P. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset.
P. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset.
read the entire text >>

Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency.
Baracchini C, Perini P, Causin F, Calabrese M, Rinaldi F, Gallo P. Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency.
read the entire text >>

Hemodynamic patterns of chronic cerebrospinal insufficiency in multiple sclerosis.
Bartomolei I, Salvi F, Galeotti R, Salviato E, Alcanterini M, Menegatti E et al. Hemodynamic patterns of chronic cerebrospinal insufficiency in multiple sclerosis. Correlation with symptoms at onset and clinical course.
read the entire text >>

Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity.
Centonze D, Floris R, Stefanini M, Rossi S, Fabiano S, Castelli M et al. Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity.
read the entire text >>

The 150th anniversary of the first depiction of the lesions of multiple sclerosis.
Compston A. The 150th anniversary of the first depiction of the lesions of multiple sclerosis.
read the entire text >>

No cerebro-cervical venous congestion in patients with multiple sclerosis.
Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ. No cerebro-cervical venous congestion in patients with multiple sclerosis.
read the entire text >>

Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis.
Laupacis A, Lillie E, Dueck A, Straus S, Perrier L, Burton JM et al. Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis.
read the entire text >>

Multiple sclerosis: a complicated picture of autoimmunity.
McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity.
read the entire text >>

Multiple sclerosis and CCSVI: a population-based control study.
Patti F, Nicoletti A, Leone C, Messina S, D’Amico E, Lo Fermo S et al. Multiple sclerosis and CCSVI: a population-based control study.
read the entire text >>

Results of treatment of multiple sclerosis with dicoumarin.
Putnam TJ, Chiavacci LY, Hoff H, Weitzen HG. Results of treatment of multiple sclerosis with dicoumarin.
read the entire text >>

Damaging venous reflux into the skull or spine: relevance to multiple sclerosis.
Schelling F. Damaging venous reflux into the skull or spine: relevance to multiple sclerosis.
read the entire text >>

Extracranial venous hemodynamics in multiple sclerosis: A case-control study.
Tsivgoulis G, Mantatzis M, Bogiatzi C, Vadikolias K, Voumvourakis K, Prassopoulos et al. Extracranial venous hemodynamics in multiple sclerosis: A case-control study.
read the entire text >>

Chronic cerebrospinal insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients.
Weinstock-Guttman B, Zivadinov R, Cutter G, Tamano-Blanco M, Marr K, Badgett D et al. Chronic cerebrospinal insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients.
read the entire text >>

Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.
Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.
read the entire text >>

Intracranial venous hemodynamics in multiple sclerosis.
Zamboni P, Menegatti E, Bartolomei I, Galeotti R, Malagoni AM, Tacconi G et al. Intracranial venous hemodynamics in multiple sclerosis.
read the entire text >>

The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis.
Zamboni P, Menegatti E, Galeotti R, Malagoni AM, Tacconi G, Dall'Ara S et al. The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis.
read the entire text >>

The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis.
Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis.
read the entire text >>

Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)
Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)
read the entire text >>

9. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 9, 2013, No. 2 , , ,

Epidemiological and Genetics Aspects of Multiple Sclerosis in Latin America.
Epidemiological and Genetics Aspects of Multiple Sclerosis in Latin America.
read the entire text >>

Correction and Evaluation of Motor Impairment in Multiple Sclerosis Patients using Biofeedback.
Correction and Evaluation of Motor Impairment in Multiple Sclerosis Patients using Biofeedback.
read the entire text >>

The detection of changes of deep brain structures on TCS in multiple sclerosis patients was found to have a predictive value for further disease progression.
basal ganglia changes also in other movement disorders such as lenticular nucleus hyperechogenicity in idiopathic dystonia and Wilson's disease and caudate nucleus hyperechogenicity in Huntington's disease. Reduced echogenicity of midbrain raphe is frequent in depressive disorders and was found to correlate with responsivity to serotonin reuptake inhibitors. An elegant application of TCS is the intraand postoperative localization of deep brain stimulation electrodes in patients with movement disorders. The detection of changes of deep brain structures on TCS in multiple sclerosis patients was found to have a predictive value for further disease progression.
read the entire text >>

In multiple sclerosis a chronic impaired cerebral venous outflow has claimed to be the starting point of a cascade leading to the disease.
The cerebral venous outflow has been neglected for many years in neurology. Considering Neurosonology a first interest started with primarily venous disorders, e.g. cerebral venous and sinus thrombosis. In the last few years venous ultrasound analysis was performed in a variety of other neurological disorders like dural fistulas, transient global amnesia and even in acute arterial stroke. In multiple sclerosis a chronic impaired cerebral venous outflow has claimed to be the starting point of a cascade leading to the disease. This concept has not been reproduced by groups with a longstanding experience in venous duplex sonography. However, the debates increased the scientific interest on the venous side of the cerebral circulation and its outflow.
read the entire text >>

EPIDEMIOLOGICAL AND GENETICS ASPECTS OF MULTIPLE SCLEROSIS IN LATIN AMERICA
EPIDEMIOLOGICAL AND GENETICS ASPECTS OF MULTIPLE SCLEROSIS IN LATIN AMERICA
read the entire text >>

genetics, Latin America, multiple sclerosis, neuroepidemiology.
genetics, Latin America, multiple sclerosis, neuroepidemiology.
read the entire text >>

10. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 10, 2014, No. 2 , , ,

Normal aging process and many different neurological disorders like stroke, dementia, Alzheimer’s and Parkinson’s disease, Huntington disease, multiple sclerosis and acquired brain trauma contribute to the decline of our cognitive abilities.
phenomenon known as "learned non use". With the loss of a brain area’s function, the body part that was linked to this area is also affected and its mobility power is lost too. As the patient can not move his most affected limb, he compensates this using the other limb. Thus, after a certain period, when the damage effects aren’t present anymore and brain adaptations happen, the movements could be recovered, but the patient has already 'learned" that the limb is no longer functional [1]. Cognitive abilities like processing speed, memory and reasoning start to decline in our late twenties. Normal aging process and many different neurological disorders like stroke, dementia, Alzheimer’s and Parkinson’s disease, Huntington disease, multiple sclerosis and acquired brain trauma contribute to the decline of our cognitive abilities.
read the entire text >>

11. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 11, 2015, No. 2 , , ,

P27 Cardiovascular Autonomic Dysfunction in Multiple Sclerosis.
P27 Cardiovascular Autonomic Dysfunction in Multiple Sclerosis.
read the entire text >>

ated with Parkinson's (PD) or Wilson's disease (WD), but not in healthy adults, schizophrenia, multiple sclerosis with depression or Parkinson's disease without concomitant depression.
ated with Parkinson's (PD) or Wilson's disease (WD), but not in healthy adults, schizophrenia, multiple sclerosis with depression or Parkinson's disease without concomitant depression.
read the entire text >>

DYSFUNCTION IN MULTIPLE SCLEROSIS
DYSFUNCTION IN MULTIPLE SCLEROSIS
read the entire text >>

Autonomic dysfunction in multiple sclerosis (MS) is most often presented with urinary symptoms, while cardiovascular are less frequently reported.
Autonomic dysfunction in multiple sclerosis (MS) is most often presented with urinary symptoms, while cardiovascular are less frequently reported. They can be evaluated with cardiovascular autonomic tests.
read the entire text >>

autonomic dysfunction, multiple sclerosis.
autonomic dysfunction, multiple sclerosis.
read the entire text >>

12. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 12, 2016, No. 1 , , ,

Apart from callosotomy, this phenomenon may be seen also in cases with multiple sclerosis, traumas, lesions in the corpus callosum in Marchiafava-Bignami disease (rare disease, characterized by demyelination of the corpus callosum in chronic alcoholism), dysgenesis of the corpus callosum, etc.
The role of the corpus callosum in the brain activity as a whole has been studied by the Noble laureate Roger Sperry (1981), who created the theory of the “split-brain” (“disconnection syndrome”). After commisurotomy in patients with epilepsy, he discovered that both hemispheres function independently and each of them performs specific functions – he calls this phenomenon “two separate minds in one brain” [2, 10, 19]. He has shown that people who write with their right hand cannot name and describe a subject held in their left hand, after commissurotomy. The patients develop cognitive deficit, have deficiency in an object thinking, short-term memory and attention deficit due to the disruption of the connection between the two hemispheres. Apart from callosotomy, this phenomenon may be seen also in cases with multiple sclerosis, traumas, lesions in the corpus callosum in Marchiafava-Bignami disease (rare disease, characterized by demyelination of the corpus callosum in chronic alcoholism), dysgenesis of the corpus callosum, etc. [2, 7]. Some authors consider that the leading role for the symptoms in dysgenesis of corpus callosum is not the severed connection between the two hemispheres, but the presence of abnormal microstructure, reduced volume of the cingulum, wrongly formed neurons in the region of the fronto-insular cortex and the anterior cortex of the cingulum [3].
read the entire text >>

in Multiple Sclerosis Congress
in Multiple Sclerosis Congress
read the entire text >>

13. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 13, 2017, No. 1 , , ,

in Multiple Sclerosis Conference
in Multiple Sclerosis Conference
read the entire text >>

14. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 13, 2017, No. 2 , , ,

Diseases like Parkinson’s disease (1.1%) or multiple sclerosis (0.6%) cause a comparatively low burden of DALY.
reaching approximately 40% within the first 30 days after the bleeding, and a higher morbidity [61]. Only approximately 20% of ICH patients are functionally independent at 6 months [49]. A recent analysis of the Global Burden of Disease Study focusing on the neurological field confirmed the important role of so called “hemorrhagic strokes” (a term including ICH and SAH) as the cause of the highest mortality and morbidity as compared to all other diseases from the neurological spectrum [8]. Looking at DisabilityAdjusted Life-Years (DALY), hemorrhagic strokes are the number one DALY cause (35.7% of DALY caused by any neurological diseases), followed by ischemic stroke with 22.4%, migraine (12.7%), epilepsy (9.9%), dementia (6.4%). Diseases like Parkinson’s disease (1.1%) or multiple sclerosis (0.6%) cause a comparatively low burden of DALY. For better understanding a DALY can be described as the loss of one healthy year of one’s life.
read the entire text >>

of Multiple Sclerosis.
of Multiple Sclerosis.
read the entire text >>

exercises, kinesitherapy, multiple sclerosis, neurorehabilitation
exercises, kinesitherapy, multiple sclerosis, neurorehabilitation
read the entire text >>

15. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 14, 2018, No. 1 , , ,

TCS revealed reduced echogenicity of the brainstem raphe (BR) as a characteristic finding in unipolar depression and in depression associated with Parkinson's (PD) or Wilson's disease (WD), but not in healthy adults, schizophrenia, multiple sclerosis with depression or Parkinson's disease without concomitant depression.
Transcranial sonography (TCS) has been recently recognized as a reliable and sensitive tool in detecting basal ganglia (BG) abnormalities in several movement disorders, where different patterned hyperechogenic lesions were demonstrated. TCS revealed reduced echogenicity of the brainstem raphe (BR) as a characteristic finding in unipolar depression and in depression associated with Parkinson's (PD) or Wilson's disease (WD), but not in healthy adults, schizophrenia, multiple sclerosis with depression or Parkinson's disease without concomitant depression.
read the entire text >>

The same structural abnormality has also been reported when depressed patients have been compared to non-depressed patients, having a variety of neurological diseases, for example, PD [4, 5], dystonic syndromes [15] and Wilson’s disease [18] but not multiple sclerosis with or without depression [6, 7].
Besides the specific finding of the substantia nigra (SN) hyperechogenicity in up to 90% of Parkinson’s disease (PD) patents, first time described in 1995 by Becker et al. [1], a series of studies using TCS has reported another specific ultrasound feature: structural abnormality of the midbrain raphe depicted as reduced echogenicity or invisible brainstem raphe (BR) in patients with unipolar depression compared with healthy individuals [2, 3]. The same structural abnormality has also been reported when depressed patients have been compared to non-depressed patients, having a variety of neurological diseases, for example, PD [4, 5], dystonic syndromes [15] and Wilson’s disease [18] but not multiple sclerosis with or without depression [6, 7].
read the entire text >>

Lesion pattern in patients with multiple sclerosis and depression.
Berg D, Supprian T, Thomae J, Warmuth-Metz M, Horowski A, Zeiler B, et al. Lesion pattern in patients with multiple sclerosis and depression.
read the entire text >>

G. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis.
G. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis.
read the entire text >>

16. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, vol. 14, 2018, No. 2 , , ,

Furthermore, SMMR studies may open ways to understand mechanisms in disorders presenting with severely altered sensory processing, such as in multiple sclerosis or autism spectrum disorders.
Cortical activations were located in contralateral postcentral gyrus after MN and RN stimulations and in bilateral operculo-insular area after RN stimulation. We also compared novel intracutaneous nociceptive stimuli to other sensory stimuli. We found variations in activation of bilateral operculo-insular areas and these may corroborate their role in pain network and also in multisensory integration. Our findings imply that these areas present a relay station in multisensory stimulus detection. SMMR is a feasible method for investigating brain’s somatosensory change detection system and it is useful as an indicator of cortical plasticity. Furthermore, SMMR studies may open ways to understand mechanisms in disorders presenting with severely altered sensory processing, such as in multiple sclerosis or autism spectrum disorders.
read the entire text >>

with Multiple Sclerosis.
with Multiple Sclerosis.
read the entire text >>

Verbal Fluency in Patients with Multiple Sclerosis – Functional MRI Study.
Verbal Fluency in Patients with Multiple Sclerosis – Functional MRI Study.
read the entire text >>

WITH MULTIPLE SCLEROSIS
WITH MULTIPLE SCLEROSIS
read the entire text >>

Multiple sclerosis (MS) is a chronic progressive disease that affects a wide range of neurological functions that cause mobility limitations, including gait and balance disturbances.
Multiple sclerosis (MS) is a chronic progressive disease that affects a wide range of neurological functions that cause mobility limitations, including gait and balance disturbances. The therapeutic program should be organized on the basis of assessment and examination of specific impairments to optimize the effectiveness of physical therapy (PT).
read the entire text >>

balance evaluation, multiple sclerosis, physical therapy
balance evaluation, multiple sclerosis, physical therapy
read the entire text >>

VERBAL FLUENCY IN PATIENTS WITH MULTIPLE SCLEROSIS – FUNKTIONAL MRI STUDY
VERBAL FLUENCY IN PATIENTS WITH MULTIPLE SCLEROSIS – FUNKTIONAL MRI STUDY
read the entire text >>

Cognitive impairment affects 40–70% of patients with multiple sclerosis and can occur in the earliest stages of the disease resulting in decreased quality of life.
Cognitive impairment affects 40–70% of patients with multiple sclerosis and can occur in the earliest stages of the disease resulting in decreased quality of life. Some of the most affected cognitive domains are verbal fluency, abstract and conceptual thinking.
read the entire text >>

To evaluate activation patterns of verbal fluency with functional magnetic resonance imaging (fMRI) in patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls.
To evaluate activation patterns of verbal fluency with functional magnetic resonance imaging (fMRI) in patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls.
read the entire text >>

fMRI, multiple sclerosis, verbal fluency
fMRI, multiple sclerosis, verbal fluency
read the entire text >>

She is Principal Investigator, National Coordinator or contributor to a number of international trials in the field of stroke, multiple sclerosis, epilepsy and Parkinson’s disease.
new directions in ultrasound diagnostics of the nervous system in Bulgaria and abroad. She is Principal Investigator, National Coordinator or contributor to a number of international trials in the field of stroke, multiple sclerosis, epilepsy and Parkinson’s disease. She has been a guest lecturer in Serbia, Croatia, Finland, Mexico and Georgia and chairperson in many national and international scientific events.
read the entire text >>

Back to Top